SCHEMBL29699397

SCHEMBL29699397

Clc1ccc(-c2cccc(-c3c[nH]nn3)c2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.45
KMO O15229 4/20 0.41
CYP1B1 Q16678 1/20 0.40
RAB9A P51151 4/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
PFKFB3 Q16875 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
NOTUM Q6P988 1/20 0.37
IDO1 P14902 1/20 0.36
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457513 1.00 AHR (0.45) AHRKMOCYP1B1RAB9AKDM4E
SCHEMBL27971304 0.92 AHR (0.48) AHRKMOCYP1B1RAB9AKDM4E
SCHEMBL30918738 0.92 AHR (0.48) AHRKMOCYP1B1RAB9AKDM4E
SCHEMBL1646236 0.84 GP6 (0.37) CYP1B1RAB9AALDH1A1CYP1A2CYP2C19
SCHEMBL29699611 0.82 KMO (0.44) KMOMAPTADORA2AADORA1HAO1
SCHEMBL23457505 0.82 KMO (0.44) KMOMAPTADORA2AADORA1HAO1
SCHEMBL1336095 0.80 IDO1 (0.50) KMORAB9AKDM4EALDH1A1NPC1
SCHEMBL29899189 0.77 KMO (0.43) KMOMAPTNOTUM
SCHEMBL6166026 0.77 CYP3A4 (0.52) KMORAB9AKDM4EALDH1A1NPC1
SCHEMBL23457485 0.74 AHR (0.41) AHRRAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 3115/4885KMO 248/4885CYP1B1 489/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 2840/4885KMO 255/4885CYP1B1 508/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT AHR 3115/4885KMO 248/4885CYP1B1 489/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT AHR 3115/4885KMO 248/4885CYP1B1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.